— Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
June 4, 2026
• 3 min read
Amarin Pharma has not done enough to definitively show that its generic competitor, Hikma Pharmaceuticals, is infringing on Amarin's patents for its anti-hypertriglyceridemia drug icosapent ethyl (Vascepa), the Supreme Court unanimously ruled Thursday.
"Amarin has failed to state a claim for active inducement ... so its complaint cannot withstand Hikma's motion," Justice Ketanji Brown Jackson wrote in the opinion. "We therefore reverse the judgment of the federal circuit and remand the case for further proceedings consistent with this opinion."
